Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis

Abstract Signals from the TGF-βs are mediated by the TGF-β receptors and their substrates, the Smad proteins. Inactivation of either of the two transmembrane serine/threonine kinases called the TGF-β type I and type II receptors is now known to underlie a wide variety of human pathologies including, especially carcinogenesis. Numerous studies have now demonstrated that the TGF-β receptor complex and its downstream signaling intermediates constitute a tumor suppressor pathway. We review here a specific pathway of mutational inactivation of the TGF-β type II receptor resulting from microsatellite instability and demonstrate that, by contrast, the most common mechanism of loss of expression of the TGF-β type II receptor involves transcriptional repression. This provides a new target for therapeutic intervention.

[1]  H. Moses,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1998.0161 , 2022 .

[2]  E. Gabrielson,et al.  The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma. , 1999, Cancer research.

[3]  K. Miyazono,et al.  HNPCC associated with germline mutation in the TGF-β type II receptor gene , 1998, Nature Genetics.

[4]  H. P. Wang,et al.  Clinicopathological significance of altered loci of replication error and microsatellite instability-associated mutations in gastric cancer. , 1998, Cancer research.

[5]  M. Sporn,et al.  Characterization of the Promoter Region of the Human Transforming Growth Factor-β Type II Receptor Gene * , 1995, The Journal of Biological Chemistry.

[6]  K. Kinzler,et al.  Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. , 1995, Cancer research.

[7]  A. Bird.  CpG-rich islands and the function of DNA methylation , 1986, Nature.

[8]  P. Sorensen,et al.  A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS–family transcription factor, ERG , 1994, Nature Genetics.

[9]  J. Willson,et al.  Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells , 1994 .

[10]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[11]  M. Monden,et al.  Mutations of the transforming growth factor β type II receptor gene and microsatellite instability in gastric cancer , 1996, International journal of cancer.

[12]  R. Seruca,et al.  The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. , 1998, The American journal of pathology.

[13]  K. Crosier,et al.  The TGF-β type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression , 1999, Leukemia.

[14]  D. Leprince,et al.  The ets gene family. , 1992, Trends in biochemical sciences.

[15]  K. Miyazono,et al.  Lack of transforming growth factor‐β type II receptor expression in human retinoblastoma cells , 1998, Journal of cellular physiology.

[16]  H. Hollema,et al.  Structural alterations of transforming growth factor‐β receptor genes in human cervical carcinoma , 1999, International journal of cancer.

[17]  J. Eshleman,et al.  Microsatellite instability in inherited and sporadic neoplasms. , 1995, Current opinion in oncology.

[18]  Luzhe Sun,et al.  Reduced Expression of Transforming Growth Factor β Type I Receptor Contributes to the Malignancy of Human Colon Carcinoma Cells* , 1996, The Journal of Biological Chemistry.

[19]  H. Lodish,et al.  Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia , 1997 .

[20]  T. Dryja,et al.  Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. , 1991, American journal of human genetics.

[21]  Wen-Lin Kuo,et al.  ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis , 1997, Oncogene.

[22]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[23]  Y. Bang,et al.  Transcriptional repression of the transforming growth factor-β type I receptor gene by DNA methylation results in the development of TGF-β resistance in human gastric cancer , 1999, Oncogene.

[24]  M. Rhyu,et al.  Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population. , 1996, Cancer research.

[25]  K. Yoshioka,et al.  Gene mutation of transforming growth factor β1 type II receptor in hepatocellular carcinoma , 1999, International journal of cancer.

[26]  K. Miyazono,et al.  Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene. , 1999, Biochemical and biophysical research communications.

[27]  J. Massagué,et al.  Loss of receptors for transforming growth factor beta in human T-cell malignancies. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Fine,et al.  Structure and expression of the promoter for the R4/ALK5 human type I transforming growth factor-β receptor: regulation by TGF-β , 1996 .

[29]  P. Steinert,et al.  The expression of a novel, epithelium-specific ets transcription factor is restricted to the most differentiated layers in the epidermis. , 1997, Nucleic acids research.

[30]  M. Makuuchi,et al.  A transforming growth factor beta type II receptor gene mutation common in sporadic cecum cancer with microsatellite instability. , 1996, Cancer research.

[31]  M. Reiss,et al.  A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression. , 1996, Cancer research.

[32]  T. Libermann,et al.  Isolation and characterization of a novel epithelium-specific transcription factor, ESE-1, a member of the ets family , 1997, Molecular and cellular biology.

[33]  M. Sporn,et al.  Peptide growth factors are multifunctional , 1988, Nature.

[34]  A. Chapelle,et al.  Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability , 1995, Nature Genetics.

[35]  L. Myeroff,et al.  Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. , 1998, Cancer research.

[36]  T. Iwama,et al.  Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. , 1997, Gastroenterology.

[37]  Anita B. Roberts,et al.  Tumor suppressor activity of the TGF-β pathway in human cancers , 1996 .

[38]  H. Lodish,et al.  A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma , 1996, Molecular and cellular biology.

[39]  D. Demetrick,et al.  Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver, and breast. , 1996, Biochemical and biophysical research communications.

[40]  J. Kleeff,et al.  Transfection of the type I TGF‐β receptor restores TGF‐β responsiveness in pancreatic cancer , 1998 .

[41]  Anita B. Roberts,et al.  Peptide Growth Factors and Their Receptors I , 1990, Springer Study Edition.

[42]  S. Baylin,et al.  Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon , 1994, Nature Genetics.

[43]  Darryl Shibata,et al.  Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis , 1993, Nature.

[44]  S. Horiike,et al.  Microsatellite instability is an early genetic event in myelodysplastic syndrome but is infrequent and not associated with TGF-beta receptor type II gene mutation. , 1996, Leukemia.

[45]  P. Sorensen,et al.  Delayed early embryonic lethality following disruption of the murine cyclin A2 gene , 1999, Nature Genetics.

[46]  R. J. Fisher,et al.  ERF: an ETS domain protein with strong transcriptional repressor activity, can suppress ets‐associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation. , 1995, The EMBO journal.

[47]  M. Ohue,et al.  Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas. , 1997, Cancer letters.

[48]  H. Cavé,et al.  Microsatellite instability and frameshift mutations in BAX and transforming growth factor-beta RII genes are very uncommon in acute lymphoblastic leukemia in vivo but not in cell lines. , 1998, Blood.

[49]  Chung Lee,et al.  Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells , 1996 .

[50]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Okamoto,et al.  Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF-beta 1 in an immortalized human esophageal epithelial cell line. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Slattery,et al.  Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas. , 1997, The American journal of pathology.

[53]  S. Takenoshita,et al.  Mutation of the transforming growth factor-beta type II receptor gene is a rare event in human sporadic gastric carcinomas. , 1998, International journal of oncology.

[54]  C. C. Harris,et al.  Analyses of mutation and loss of heterozygosity of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human gastric cancer. , 1998, Carcinogenesis.

[55]  Robin J. Leach,et al.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer , 1993, Cell.

[56]  Y. Song,et al.  Genetic integrity of transforming growth factor β (TGF‐β) receptors in cervical carcinoma cell lines: loss of growth sensitivity but conserved transcriptional response to TGF‐β , 1998 .

[57]  E. Dmitrovsky,et al.  Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. , 1998, Cancer research.

[58]  M. Reiss.  Transforming growth factor-beta and cancer: a love-hate relationship? , 1997, Oncology research.

[59]  Y. Nagamachi,et al.  Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-beta type II receptor gene in sporadic human breast cancers. , 1998, Oncology reports.

[60]  P. Jones,et al.  DNA methylation errors and cancer. , 1996, Cancer research.

[61]  J. Yokota,et al.  RER phenotype and its associated mutations in familial gastric cancer. , 1998, Carcinogenesis.

[62]  Marcienne M Wright,et al.  EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic , 1997, Nature Genetics.

[63]  M Reiss,et al.  Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells. , 1997, Oncology research.

[64]  T. Enomoto,et al.  Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. , 1998, Cancer research.

[65]  J. Yokota,et al.  Infrequent mutations of the transforming growth factor beta-type II receptor gene at chromosome 3p22 in human lung cancers with chromosome 3p deletions. , 1997, Carcinogenesis.

[66]  K. Kinzler,et al.  Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. , 1999, Cancer research.

[67]  Y. Bang,et al.  Truncation of the TGF-β type II receptor gene results in insensitivity to TGF-β in human gastric cancer cells , 1999, Oncogene.

[68]  Y. Yuasa,et al.  Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. , 1995, Biochemical and biophysical research communications.

[69]  Jay H. Chang,et al.  Mechanism of E1A-Induced Transforming Growth Factor-β (TGF-β) Resistance in Mouse Keratinocytes Involves Repression of TGF-β Type II Receptor Transcription* , 1997, The Journal of Biological Chemistry.

[70]  M. Reiss,et al.  Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. , 1998, Cancer research.

[71]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[72]  N. Copeland,et al.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer , 1993, Cell.

[73]  M. Sporn,et al.  Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Martin Rosenberg,et al.  A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer , 1997, Oncogene.

[75]  A. Klibanski,et al.  Mutational analysis of activin/transforming growth factor-beta type I and type II receptor kinases in human pituitary tumors. , 1999, The Journal of clinical endocrinology and metabolism.

[76]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[77]  A. Marchetti,et al.  Microsatellite alterations and p53, TGFβRII, IGFIIR and BAX mutations in sporadic non‐small‐cell lung cancer , 1998, International journal of cancer.

[78]  Chen-Yang Shen,et al.  Frequent aberration of the transforming growth factor‐β receptor II gene in cell lines but no apparent mutation in pre‐invasive and invasive carcinomas of the uterine cervix , 1999, International journal of cancer.

[79]  K. Kinzler,et al.  Clues to the pathogenesis of familial colorectal cancer. , 1993, Science.

[80]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[81]  M. Klemsz,et al.  Characterization of the ets oncogene family member, fli-1. , 1993, The Journal of biological chemistry.

[82]  Seong-Jin Kim,et al.  Transforming growth factor-β receptors: Role in physiology and disease , 1996 .

[83]  M. Sporn,et al.  The Transforming Growth Factor-βs , 1991 .

[84]  Luzhe Sun,et al.  Induction of Transforming Growth Factor-β Receptor Type II Expression in Estrogen Receptor-positive Breast Cancer Cells through SP1 Activation by 5-Aza-2′-deoxycytidine* , 1998, The Journal of Biological Chemistry.

[85]  H. Sugimura,et al.  Transforming growth factor J3 type II receptor (TGFpRII) mutation in gastric lymphoma without mutator phenotype , 1998 .

[86]  Y. Kawarada,et al.  Analysis of microsatellite instability, TGF-beta type II receptor gene mutations and hMSH2 and hMLH1 allele losses in pancreaticobiliary maljunction-associated biliary tract tumors. , 1999, Anticancer research.

[87]  Gerald M. Rubin,et al.  Negative control of photoreceptor development in Drosophila by the product of the yan gene, an ETS domain protein , 1992, Cell.

[88]  Keunchil Park,et al.  Expression of Transforming Growth Factor β Type II Receptor Reduces Tumorigenicity in Human Gastric Cancer Cells , 1997 .

[89]  S. Hirohashi,et al.  Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[90]  C. Denny,et al.  A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. , 1995, Oncogene.

[91]  Y. Yuasa,et al.  Genetic alterations are frequent in APC but rare in the TGF-beta type II receptor gene in cancer in adenomas of the colon. , 1998, Cancer letters.

[92]  Y. Yuasa,et al.  Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. , 1996, Cancer research.

[93]  Y. Chung,et al.  Relationship between intratumor histological heterogeneity and genetic abnormalities in gastric carcinoma with microsatellite instability , 1999 .

[94]  Y. Bang,et al.  A Novel ets-related Transcription Factor, ERT/ESX/ESE-1, Regulates Expression of the Transforming Growth Factor-β Type II Receptor* , 1998, The Journal of Biological Chemistry.

[95]  H. Bismuth,et al.  Microsatellite instability in European hepatocellular carcinoma , 1999, Oncogene.

[96]  R. Weinberg,et al.  Absence of TGF-beta receptors and growth inhibitory responses in retinoblastoma cells. , 1988, Science.

[97]  C. Denny,et al.  Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[98]  H. Kuwano,et al.  Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. , 1999, International journal of oncology.

[99]  C. Missero,et al.  Induction of transforming growth factor beta 1 resistance by the E1A oncogene requires binding to a specific set of cellular proteins. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[100]  Kathleen R. Cho,et al.  A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. , 1995, Cancer research.